Another interesting study of MSH2 behavior in cells exposed to the same MNNG alkylating treatment used an MSH2-null human endometrial cancer cell line (Hec59) and then investigated behavior of a set of MSH2 mutants, along with wild-type MSH2 as a control [63]. This evidence concerns the gene MSH2 and endometrial cancer.